後期慢性腎臓病治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE2415)
◆英語タイトル:Global Late Stage Chronic Kidney Disease Drugs Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE2415
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:107
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、後期慢性腎臓病治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(カルシウム受容体刺激薬、ビタミンDステロール、カリウムバインダー、その他)、用途別市場規模(病院薬局、オンライン薬局、小売薬局)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・後期慢性腎臓病治療薬の市場動向
・企業の競争状況、市場シェア
・後期慢性腎臓病治療薬の種類別市場規模(カルシウム受容体刺激薬、ビタミンDステロール、カリウムバインダー、その他)
・後期慢性腎臓病治療薬の用途別市場規模(病院薬局、オンライン薬局、小売薬局)
・後期慢性腎臓病治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・後期慢性腎臓病治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・後期慢性腎臓病治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・後期慢性腎臓病治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・後期慢性腎臓病治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(AbbVie、Amgen、Ardelyx、AstraZeneca、Deltanoid、Akebia Therapeutics、Kyowa Hakko Kirin、OPKO Health、Vifor Pharma、Sanofi、Shield Therapeutics、Shire、Spectrum、ZS Pharma)
・結論
【レポートの概要】

Late stage chronic kidney disease therapeutics can be defined as the drugs which are used for the treatment of late-stage CKD – Induced, Hyperphosphatemia, Hyperparathyroidism and Hyperkalemia.

Market Analysis and Insights: Global Late Stage Chronic Kidney Disease Drugs Market
The global Late Stage Chronic Kidney Disease Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Late Stage Chronic Kidney Disease Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Late Stage Chronic Kidney Disease Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Late Stage Chronic Kidney Disease Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Late Stage Chronic Kidney Disease Drugs market.

Global Late Stage Chronic Kidney Disease Drugs Scope and Market Size
Late Stage Chronic Kidney Disease Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Late Stage Chronic Kidney Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Calcimimetics
Vitamin D Sterols
Potassium Binders
Others

Segment by Application
Hospital Pharmacies
Online Pharnacies
Retail Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Amgen
Ardelyx
AstraZeneca
Deltanoid
Akebia Therapeutics
Kyowa Hakko Kirin
OPKO Health
Vifor Pharma
Sanofi
Shield Therapeutics
Shire
Spectrum
ZS Pharma

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Calcimimetics
1.2.3 Vitamin D Sterols
1.2.4 Potassium Binders
1.2.5 Others
1.3 Market by Application
1.3.1 Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Online Pharnacies
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Late Stage Chronic Kidney Disease Drugs Market Perspective (2016-2027)
2.2 Late Stage Chronic Kidney Disease Drugs Growth Trends by Regions
2.2.1 Late Stage Chronic Kidney Disease Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Late Stage Chronic Kidney Disease Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Late Stage Chronic Kidney Disease Drugs Industry Dynamic
2.3.1 Late Stage Chronic Kidney Disease Drugs Market Trends
2.3.2 Late Stage Chronic Kidney Disease Drugs Market Drivers
2.3.3 Late Stage Chronic Kidney Disease Drugs Market Challenges
2.3.4 Late Stage Chronic Kidney Disease Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue
3.1.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue (2016-2021)
3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Late Stage Chronic Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue
3.4 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio
3.4.1 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Late Stage Chronic Kidney Disease Drugs Revenue in 2020
3.5 Late Stage Chronic Kidney Disease Drugs Key Players Head office and Area Served
3.6 Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service
3.7 Date of Enter into Late Stage Chronic Kidney Disease Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Late Stage Chronic Kidney Disease Drugs Breakdown Data by Type
4.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Type (2016-2021)
4.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2022-2027)

5 Late Stage Chronic Kidney Disease Drugs Breakdown Data by Application
5.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Application (2016-2021)
5.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Late Stage Chronic Kidney Disease Drugs Market Size (2016-2027)
6.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type
6.2.1 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2021)
6.2.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2022-2027)
6.2.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2027)
6.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application
6.3.1 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2021)
6.3.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2022-2027)
6.3.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2027)
6.4 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country
6.4.1 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2016-2021)
6.4.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size (2016-2027)
7.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type
7.2.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2021)
7.2.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2022-2027)
7.2.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2027)
7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application
7.3.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2021)
7.3.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2022-2027)
7.3.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2027)
7.4 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country
7.4.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2016-2021)
7.4.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size (2016-2027)
8.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type
8.2.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application
8.3.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region
8.4.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size (2016-2027)
9.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type
9.2.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2027)
9.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application
9.3.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2027)
9.4 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country
9.4.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size (2016-2027)
10.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type
10.2.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application
10.3.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country
10.4.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Introduction
11.1.4 AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Introduction
11.2.4 Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Ardelyx
11.3.1 Ardelyx Company Details
11.3.2 Ardelyx Business Overview
11.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Introduction
11.3.4 Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.3.5 Ardelyx Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Introduction
11.4.4 AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.4.5 AstraZeneca Recent Development
11.5 Deltanoid
11.5.1 Deltanoid Company Details
11.5.2 Deltanoid Business Overview
11.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Introduction
11.5.4 Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.5.5 Deltanoid Recent Development
11.6 Akebia Therapeutics
11.6.1 Akebia Therapeutics Company Details
11.6.2 Akebia Therapeutics Business Overview
11.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
11.6.4 Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.6.5 Akebia Therapeutics Recent Development
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Details
11.7.2 Kyowa Hakko Kirin Business Overview
11.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Introduction
11.7.4 Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.7.5 Kyowa Hakko Kirin Recent Development
11.8 OPKO Health
11.8.1 OPKO Health Company Details
11.8.2 OPKO Health Business Overview
11.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Introduction
11.8.4 OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.8.5 OPKO Health Recent Development
11.9 Vifor Pharma
11.9.1 Vifor Pharma Company Details
11.9.2 Vifor Pharma Business Overview
11.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Introduction
11.9.4 Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.9.5 Vifor Pharma Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Details
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Introduction
11.10.4 Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.10.5 Sanofi Recent Development
11.11 Shield Therapeutics
11.11.1 Shield Therapeutics Company Details
11.11.2 Shield Therapeutics Business Overview
11.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction
11.11.4 Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.11.5 Shield Therapeutics Recent Development
11.12 Shire
11.12.1 Shire Company Details
11.12.2 Shire Business Overview
11.12.3 Shire Late Stage Chronic Kidney Disease Drugs Introduction
11.12.4 Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.12.5 Shire Recent Development
11.13 Spectrum
11.13.1 Spectrum Company Details
11.13.2 Spectrum Business Overview
11.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Introduction
11.13.4 Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.13.5 Spectrum Recent Development
11.14 ZS Pharma
11.14.1 ZS Pharma Company Details
11.14.2 ZS Pharma Business Overview
11.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Introduction
11.14.4 ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2016-2021)
11.14.5 ZS Pharma Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 後期慢性腎臓病治療薬の世界市場規模・現状・予測2021年-2027年(Global Late Stage Chronic Kidney Disease Drugs Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。